Хроническая спонтанная крапивница: диагностические и прогностические маркеры

DOI: https://doi.org/10.29296/25877305-2020-07-02
Скачать статью в PDF
Номер журнала: 
7
Год издания: 
2020

Е.В. Бурыгина, Я.И. Козлова, кандидат медицинских наук, Н.Н. Климко, доктор медицинских наук,
профессор Северо-Западный государственный медицинский университет им. И.И. Мечникова, Санкт-Петербург
E-mail: katerina.prokura@gmail.com

Хроническая спонтанная крапивница (ХСК) – заболевание, связанное с дегрануляцией тучных клеток и появлением волдырей, зуда и (или) ангиоотеков в течение >6 нед при отсутствии специфических триггеров. Медико-социальное значение ХСК обусловлено широкой распространенностью, развитием преимущественно у лиц трудоспособного возраста, выраженным снижением качества жизни пациентов и высоким уровнем затрат на лечение. Иммунопатогенетические механизмы развития ХСК могут существенно варьировать у разных больных. Поиск новых клинических и лабораторных маркеров ХСК, способных помочь определить лучший терапевтический подход, отследить изменения в активности заболевания, предсказать ответ на терапию, является актуальной задачей современной медицины.
Ключевые слова: 
аллергология
дерматология
хроническая спонтанная крапивница
маркеры
прогноз
эффективность терапии
Для цитирования
Е.В. Бурыгина, Я.И. Козлова, Н.Н. Климко Хроническая спонтанная крапивница: диагностические и прогностические маркеры . Врач, 2020; (7): 10-17 https://doi.org/10.29296/25877305-2020-07-02

It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

Список литературы: 
  1. Zuberbier T., Aberer W., Asero R. et al. The EAACI/GA2LEN/EDF/ WAO guideline for the definition, classification, diagnosis and management of urticaria. Allergy Eur J Allergy Clin Immunol. 2018; 73: 1393–414. DOI: 10.1111/all.13397
  2. Данилычева И.В. Новый европейский согласительный документ по диагностике и ведению хронической крапивницы. Что нового? Российский аллергологический журнал. 2018; 15 (4): 54–61 [Danilycheva I.V. New European urticaria guideline. What’s new? Russian Allergology Journal. 2018; 15 (4): 54–61 (in Russ)].
  3. Lee N., Lee J.D., Lee H.Y. et al. Epidemiology of Chronic Urticaria in Korea Using the Korean Health Insurance Database, 2010–2014. Allergy Asthma Immunol Res. 2017; 9 (5): 438–45. DOI: 10.4168/aair.2017.9.5.438
  4. Colgecen E., Kemal O., Gul A.I. et al. Evaluation of Etiological Factors in Patients with Chronic Urticaria. Acta Dermatovenerol Croat. 2015; 23 (1): 36–42.
  5. Kolkhir P., Church M.K., Weller K. et al. Autoimmune chronic spontaneous urticaria: what we know and what we do not know. J Allergy Clin Immunol. 2017; 139: 1772–81.e1. DOI: 10.1016/j.jaci.2016.08.050
  6. Curto-Barredo L., Archilla L.R., Vives G.R. et al. Clinical Features of Chronic Spontaneous Urticaria that Predict Disease Prognosis and Refractoriness to Standard Treatment. Acta Derm Venereol. 2018; 98 (7): 641–7. DOI: 10.2340/00015555-2941
  7. Schmetzer O., Lakin E., Topal F.A. et al. IL-24 is a common and specific autoantigen of IgE in patients with chronic spontaneous urticaria. J Allergy Clin Immunol. 2018; 142: 876–82. DOI: 10.10 16/j.jaci.2017.10.035
  8. Puxeddu I., Petrelli F., Angelotti F. et al. Biomarkers In Chronic Spontaneous Urticaria: Current Targets And Clinical Implications. J Asthma Allergy. 2019; 12: 285–95. DOI: 10.2147/JAA.S184986
  9. Stull D., McBride D., Tian H. et al. Analysis of disease activity categories in chronic spontaneous/idiopathic urticaria. Br J Dermatol. 2017; 177: 1093–101. DOI: 10.1111/bjd.15454
  10. Sánchez-Borges M., Caballero-Fonseca F., Capriles-Hulett A. et al. Factors linked to disease severity and time to remission in patients with chronic spontaneous urticaria. J Eur Acad Dermatology Venereol. 2017; 31 (6): 964–97. DOI: 10.1111/jdv.14221
  11. Amsler E., Augey F., Soria A.et al. Chronic urticaria and hormones: is there a link? J Eur Acad Dermatol Venereol. 2016; 30 (9): 1527–30. DOI: 10.1111/jdv.13644
  12. Hiragun M., Hiragun T., Mihara S. et al. Prognosis of chronic spontaneous urticaria in 117 patients not controlled by a standard dose of antihistamine. Allergy Eur J Allergy Clin Immunol. 2013; 68 (2): 229–35. DOI: 10.1111/all.12078
  13. Sánchez-Borges M., Caballero-Fonseca F., Capriles-Hulett A. et al. Aspirin-exacerbated cutaneous disease (AECD) is a distinct subphenotype of chronic spontaneous urticaria. J Eur Acad Dermatol Venereol. 2015; 29 (4): 698–701. DOI: 10.1111/jdv.12658
  14. Sánchez-Borges M., Tassinari S., Flores A. Epidemiologic features in patients with antihistamine-resistant chronic urticaria. Rev Alerg Mex. 2015; 62 (4): 279–86.
  15. Metz M., Giménez-Arnau A., Borzova E. et al. Frequency and clinical implications of skin autoreactivity to serum versus plasma in patients with chronic urticaria. Allergy Clin Immunol. 2009; 123: 705–6. DOI: 10.1016/j.jaci.2008.11.040
  16. Mosquera L., Milena K., Moya Camacho B. et al. The Autologous Serum Skin Test as a Prognostic Factor for the Severity and Duration of Chronic Urticaria after five years of Follow-up. J Allergy Clin Immunol. 2018; 141 (2): AB46.
  17. Grattan C., Dawn G., Gibbs S. et al. Blood basophil numbers in chronic ordinary urticaria and healthy controls: diurnal variation, influence of loratadine and prednisolone and relationship to disease activity. Clin Exp Allergy. 2003; 33: 337–41. DOI: 10.1046/j.1365-2222.2003.01589.x
  18. Kolkhir P., Church M.K., Altrichter S. et al. Eosinopenia in Chronic Spontaneous Urticaria Is Associated with High Disease Activity, Autoimmunity and Poor Response to Treatment. J Allergy Clin Immunol Pract. 2020; 8 (1): 318–25.e5. DOI: 10.1016/j.jaip.2019.08.025
  19. Rorsman H. Basopenia in urticaria. Acta Allergol. 1961; 16: 185–215. DOI: 10.1111/j.1398-9995.1961.tb02894.x
  20. Rauber M.M., Pickert J., Holiangu L. et al. Functional and phenotypic analysis of basophils allows determining distinct subtypes in patients with chronic urticaria. Allergy. 2017; 72: 1904–11. DOI: 10.1111/all.13215
  21. Magen E., Mishal J., Zeldin Y. et al. Increased mean platelet volume and C-reactive protein levels in patients with chronic urticaria with a positive autologous serum skin test. Am J Med Sci. 2010; 339: 504–8. DOI: 10.1097/MAJ.0b013e3181db6ed5
  22. Kolkhir P., André F., Church M.K. et al. Potential blood biomarkers in chronic spontaneous urticaria. Clin Exp Allergy. 2017; 47: 19–36. DOI: 10.1111/cea.12870
  23. Tedeschi A., Asero R., Lorini M. et al. Plasma levels of matrix metalloproteinase-9 in chronic urticaria patients correlate with disease severity and C-reactive protein but not with circulating histamine-releasing factors. Clin Exp Allergy. 2010; 40: 875–81. DOI: 10.1111/j.1365-2222.2010.03473.x
  24. Kolkhir P., Altrichter S., Hawro T. et al. C-reactive protein is linked to disease activity, impact, and response to treatment in patients with chronic spontaneous urticaria. Allergy Eur J Allergy Clin Immunol. 2018; 73 (4): 940–8. DOI: 10.1111/all.13352
  25. Asero R. Severe CSU and activation of the coagulation/fibrinolysis system: clinical aspects. Eur Ann Allergy Clin Immunol. 2019; 52 (1): 15–7. DOI: 10.23822/EurAnnACI.1764-1489.109
  26. Kasperska-Zajac A., Grzanka A., Damasiewicz-Bodzek A. IL-6 transsignaling in patients with chronic spontaneous urticaria. PLoS One. 2015; 10 (12): e0145751. DOI: 10.1371/journal.pone.0145751
  27. Puxeddu I., Italiani P., Giungato P. et al. Free IL-18 and IL-33 cytokines in chronic spontaneous urticaria. Cytokine. 2013; 61 (3): 741–3. DOI: 10.1016/j.cyto.2013.01.015
  28. Atwa M.A., Emara A.S., Youssef N. et al. Serum concentration of IL-17, IL-23 and TNF-α among patients with chronic spontaneous urticaria: association with disease activity and autologous serum skin test. J Eur Acad Dermatol Venereol. 2014; 28 (4): 469–74. DOI: 10.1111/jdv.12124
  29. Raap U., Wieczorek D., Gehring M. et al. Increased levels of serum IL-31 in chronic spontaneous urticaria. Exp Dermatol. 2010; 19 (5): 464–6. DOI: 10.1111/j.1600-0625.2010.01067.x
  30. Bae Y., Kang S.H., Park J.O. et al. Serum transglutaminase 2 activity as a potential biomarker of disease severity and response to omalizumab in chronic spontaneous urticaria. Allergol Int. 2019; 69 (2): 304–6. DOI: 10.1016/j.alit.2019.10.009 [Online ahead of print]
  31. Ye Y.M., Yang E.M., Yoo H.S. et al. Increased level of basophil CD203c expression predicts severe chronic urticaria. J Korean Med Sci. 2014; 29: 43. DOI: 10.3346/jkms.2014.29.1.43
  32. Woo Y.R., Jung K.E., Koo D.W. et al. Vitamin D as a marker for disease severity in chronic urticaria and its possible role in pathogenesis. Ann Dermatol. 2015; 27: 423. DOI: 10.5021/ad.2015.27.4.423
  33. Trinh H.K.T., Le P.D., Ban G.Y. et al. Altered systemic adipokines in patients with chronic urticaria. Int Arch Allergy Immunol. 2016; 171 (2): 102–10. DOI: 10.1159/000452626
  34. Huilan Z., Bihua L., Runxiang L. et al. Features of antihistamine-resistant chronic urticaria and chronic urticaria during exacerbation. Indian J Dermatol. 2015; 60: 323. DOI: 10.4103/0019-5154.156458
  35. Bèlot V., Desbois I., Martin L. et al. Assessment of the usefulness of autologous serum skin testing in chronic urticaria: A retrospective single-centre study of 74 patients. Ann Dermatol Venereol. 2010; 137: 444–50. DOI: 10.1016/j.annder.2010.04.014
  36. Kolkhir P., Pogorelov D., Olisova O. CRP, D-Dimer, fibrinogen and ESR as predictive markers of response to standard doses of levocetirizine in patients with chronic spontaneous urticaria. Eur Ann Allergy Clin Immunol. 2017; 49 (4): 189–92. DOI: 10.23822/EurAnnACI.1764-1489.05
  37. Gericke J., Metz M., Ohanyan T. et al. Serum autoreactivity predicts time to response to omalizumab therapy in chronic spontaneous urticaria. J Allergy Clin Immunol Pract. 2016; 4: 529-30. DOI: 10.1016/j.jaci.2016.07.047
  38. Straesser M.D., Oliver E., Palacios T. et al. Serum IgE as an immunological marker to predict response to omalizumab treatment in symptomatic chronic urticaria. J Allergy Clin Immunol Pract. 2018; 6: 1386–8. DOI: 10.1016/j.jaip.2017.10.030
  39. Weller K., Ohanyan T., Hawro T. et al. Total IgE levels are linked to the response of chronic spontaneous urticaria patients to omalizumab. Allergy Eur J Allergy Clin Immunol. 2018; 73: 2406–8. DOI: 10.1111/all.13586
  40. Asero R., Marzano A.V., Ferrucci S. et al. D-Dimer plasma levels parallel the clinical response to omalizumab in patients with severe chronic spontaneous urticaria. Int Arch Allergy Immunol. 2017; 172: 40–4. DOI: 10.1159/000453453
  41. Altrichter S., Hawro T., Hänel K. et al. Successful omalizumab treatment in chronic spontaneous urticaria is associated with lowering of serum IL-31 levels. J Eur Acad Dermatology Venereol. 2016; 30 (3): 454–5. DOI:10.1111/jdv.12831
  42. Deza G., Bertolin-Colilla M., Pujol R.M. et al. Basophil FcεR1 expression in chronic spontaneous urticaria: a potential immunological predictor of response to omalizumab therapy. Acta Derm Venereol. 2017; 97: 698–704. DOI: 10.2340/00015555-2654
  43. Metz M., Staubach P., Bauer A. et al. Clinical efficacy of omalizumab in chronic spontaneous urticaria is associated with a reduction of FcεRI-positive cells in the skin. Theranostics. 2017; 7: 1266–76. DOI: 10.7150/thno.18304
  44. Palacios T., Stillman L., Borish L. et al. Lack of basophil CD203c-upregulating activity as an immunological marker to predict response to treatment with omalizumab in patients with symptomatic chronic urticaria. J Allergy Clin Immunol Pract. 2016; 4: 529–30. DOI: 10.1016/j.jaip.2015.11.025
  45. Ertaş R., Hawro T., Altrichter S. et al. Antinuclear antibodies are common and linked to poor response to omalizumab treatment in patients with CSU. Allergy. 2019; 75 (2): 468–70. DOI: 10.1111/all.14033. [Online ahead of print]
  46. Kulthanan K., Subchookul C., Hunnangkul S. et al. Factors Predicting the Response to Cyclosporin Treatment in Patients With Chronic Spontaneous Urticaria: A Systematic Review. Allergy Asthma Immunol Res. 2019; 11 (5): 736–55. DOI: 10.4168/aair.2019.11.5.736
  47. Iqbal K., Bhargava K., Skov P.S. et al. A positive serum basophil histamine release assay is a marker for cyclosporine responsiveness in patients with chronic spontaneous urticarial. Clin Transl Allergy. 2012; 2: 19. DOI: 10.1186/2045-7022-2-19
  48. Baek Y.S., Jeon J., Kim J.H. et al. Severity of acute and chronic urticaria correlates with D-dimer level, but not C-reactive protein or total IgE. Clin Exp Dermatol. 2014; 39: 795–800. DOI: 10.1111/ced.12413
  49. Asero R. Plasma D-dimer levels and clinical response to cyclosporine in severe chronic spontaneous urticaria. J Allergy Clin Immunol. 2015; 135: 1401–3. DOI: 10.1016/j.jaci.2014.11.016
  50. Santiago L., Ferreira B., Ramos L. et al. IgE levels are negatively correlated with clinical response to ciclosporin in chronic spontaneous urticaria. Br J Dermatol. 2019; 180: 199–200. DOI: 10.1111/bjd.17005